Amendments to the Claims

1.–22. (canceled).

23. (currently amended): [[A]] The method according to claim [[22]] 36 wherein said protein is selected from the group comprising enzymes, antibodies, antigens, hormones and cytokines.

24. (currently amended): [[A]] The method according to claim 23 wherein said therapeutically active protein is a hormone.

25. (currently amended): [[A]] The method according to claim 24 wherein said hormone is insulin.

26. (currently amended): [[A]] The method according to claim 23 wherein said protein is a cytokine.

27. (currently amended): [[A]] The method according to claim 26 wherein said cytokine is Factor VIII.

28. (currently amended): [[A]] The method according to claim [[22]] 36 wherein the particle size of said protein is from about 0.01 [[μ]] μm to about 10.0 [[μ]] μm.

29. (currently amended): [[A]] The method according to claim 28 wherein the particle size of said protein is from about [[5.0 μ]] 0.01 μm to about [[10.0 μ]] 5.0 μm.

30. (currently amended): [[A]] The method according to claim 29 wherein the particle size of said protein is from about 0.01 [[μ]] μm to about 3.0 [[μ]] μm.

31.–35. (canceled).

36. (new): A method for delivering a therapeutically active protein to the respiratory tract of a patient in need of treatment comprising the steps of:

a) preparing a liquid carrier vehicle consisting essentially of:

i) about 100% v/v substantially anhydrous ethanol; and

ii) from about 0.05% to about 5.0 w/v of a pharmaceutically acceptable excipient;

b) suspending a pharmaceutically effective amount of said protein in said liquid carrier vehicle to produce a suspension;

c) producing an aerosol of said suspension using an electrohydrodynamic spraying/aerosolization means; and

d) administering said aerosol to the pulmonary tract of said patient via inhalation of said aerosol.

37. (new): The method according to claim 36 wherein said substantially anhydrous ethanol contains less than 3.0% v/v water.

38. (new): The method according to claim 25 wherein said insulin is present in the suspension at a concentration of from about 1.0 mg/ml to about 200.0 mg/ml of said suspension.

39. (new): The method according to claim 38 wherein the particle size of said insulin is from about 0.01 μm to about 5.0 μm.

40. (new): The method according to claim 36 wherein said pharmaceutically acceptable excipient is present ins aid liquid carrier at from about 0.05% w/v to about 5.0% w/v of said carrier.

41. (new): The method according to claim 40 wherein said pharmaceutically acceptable excipient is a suspending agent.